IMMUTEP LIMITED - AMER

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

17 4月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

31 3月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

30 3月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

23 3月 2023 07:00:00 条件 Nasdaq GlobeNewswire

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

14 3月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

06 2月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

30 1月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

04 1月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

23 12月 2022 07:00:00 条件 Nasdaq GlobeNewswire

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

08 12月 2022 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

06 12月 2022 07:00:01 条件 Nasdaq GlobeNewswire

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

02 12月 2022 07:00:00 条件 Nasdaq GlobeNewswire

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

29 11月 2022 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Receives Australian R&D Tax Incentive

14 11月 2022 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

10 11月 2022 10:10:00 条件 Nasdaq GlobeNewswire

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

10 11月 2022 08:00:02 条件 Nasdaq GlobeNewswire

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

09 11月 2022 07:00:01 条件 Nasdaq GlobeNewswire

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

04 11月 2022 07:00:00 条件 Nasdaq GlobeNewswire

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

02 11月 2022 07:00:03 条件 Nasdaq GlobeNewswire

Immutep to Participate in Two Upcoming Investor Conferences

01 11月 2022 18:59:04 条件 Nasdaq GlobeNewswire